Table 1.

	Alkylisting agent class	Topoisomerase II inhibitor class
Cytogenetics	det(5q)–7/del(7q)	t(11q23.3), t(21q22.1)
Frequency	70% of t-MN patients	30% of t-MN patients
Latency	5–7 years	2–3 years
Presentation	MDS	AML
Implicated drugs	Atkylating agents: benclamustine, busulfan, carmustine, chlorambucil, cyclophosphamide, dacarbazine, lornustine, melphalan, mitomycin C, nitrogen mustard, procarbazine, thiotepa Platinum-based agents: cisplatin, carboplatin Antimetabolite agents: azathioprine, fludarabine	Anthracyclins: dauronobicini, epirubicin, doxorubicin Other topoisomerase II inhibitors: etoposide, ten iposide, amsacrine, mitoxantfone

^*Loss of the short arm of chrornosome 17 containing the TP5 3 gene due to del(17p) unbalanced rearrangement or —17 k ‘observed in asseciation with del(5q) in 40% of cases. AML. acute myeloid leukaemia: MDS, myeloid neoplasm. myelodysplastic syndrome: t-MNI. therapy-related.

By McNerney et Al.²³ Nat Rev Cancer. 2017.